Source:http://linkedlifedata.com/resource/pubmed/id/19741727
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2009-12-17
|
| pubmed:abstractText |
The objective of this study for newly diagnosed acute promyelocytic leukemia (APL) was to evaluate the efficacy of an intensified double induction chemotherapy including high dose ara-C (HD) and all-trans retinoic acid (ATRA) followed by consolidation and 3 years maintenance therapy. In contrast to APL studies stratifying therapy according to pretreatment white blood cell (WBC) count < and > or =10 x 10(9)/l (low/intermediate and high risk according to the Sanz score), our patients received uniform therapy. From 1994 to 2005, 142 patients (age, 16-60 years) were enrolled. In the low/intermediate (n=105) vs high (n=37) WBC group, the rates of complete remission were 95.2 vs 83.8%, of induction death were 4.8 vs 16.2% (P=0.05) and of molecular remission were 87.5 vs 91.3% (P=1). Long-term overall survival was 84.4 vs 73.0% (P=0.12), event free survival was 78.3 vs 67.3% (P=0.11), relapse free survival was 82.1 vs 80.0% (P=0.83) and the cumulative incidence of relapse was 7.4 vs 11.4% (P=0.46). No relapse or death occurred after 4.7 years. ATRA and intensified chemotherapy including HD ara-C followed by prolonged maintenance therapy reduced the relapse risk in high risk patients. Pretreatment WBC count > or =10 x 10(9)/l count was no relevant prognostic factor for relapse.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1476-5551
|
| pubmed:author |
pubmed-author:AulCC,
pubmed-author:BüchnerTT,
pubmed-author:BerdelW EWE,
pubmed-author:BraessJJ,
pubmed-author:German AML Cooperative Group,
pubmed-author:GrüneisenAA,
pubmed-author:HaferlachCC,
pubmed-author:HaferlachTT,
pubmed-author:HehlmannRR,
pubmed-author:HeineckeAA,
pubmed-author:HiddemannWW,
pubmed-author:KernWW,
pubmed-author:LengfelderEE,
pubmed-author:LudwigW-DWD,
pubmed-author:ReichleAA,
pubmed-author:SauerlandM-CMC,
pubmed-author:SausseleSS,
pubmed-author:SchnittgerSS,
pubmed-author:SchultheisBB,
pubmed-author:ServeHH,
pubmed-author:SpiekermannKK,
pubmed-author:StahlMM,
pubmed-author:WörmannBB
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2248-58
|
| pubmed:meshHeading |
pubmed-meshheading:19741727-Adolescent,
pubmed-meshheading:19741727-Adult,
pubmed-meshheading:19741727-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19741727-Cytarabine,
pubmed-meshheading:19741727-Germany,
pubmed-meshheading:19741727-Humans,
pubmed-meshheading:19741727-Leukemia, Promyelocytic, Acute,
pubmed-meshheading:19741727-Longitudinal Studies,
pubmed-meshheading:19741727-Lymphocyte Count,
pubmed-meshheading:19741727-Middle Aged,
pubmed-meshheading:19741727-Prognosis,
pubmed-meshheading:19741727-Remission Induction,
pubmed-meshheading:19741727-Survival Analysis,
pubmed-meshheading:19741727-Treatment Outcome,
pubmed-meshheading:19741727-Tretinoin,
pubmed-meshheading:19741727-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.
|
| pubmed:affiliation |
III. Medizinische Universitätsklinik Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim, Germany. eva.lengfelder@umm.de
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|